| Literature DB >> 35833048 |
Bhupesh Guleria1, S Viswanath2, Dharmesh Soneji3, Rajan Kapoor4, Prerna Guleria5, P Suresh3, Manish Kumar3, Amol Patel6, Shivshankar Swamy3.
Abstract
Bhupesh GuleriaAims Adolescent and young adults (AYAs), children with cancer, and their guardians have unique psychosocial morbidities adversely effecting quality of life (QOL). This is measurable using patented tools. We analyzed epidemiological and clinicopathological patterns of solid organ cancers in this subgroup. We also assessed psychosocial morbidity and changes in QOL faced by them. Methods All patients aged 2 to 39 years, newly diagnosed with cancer from April 2017 to March 2019 were included. Clinical history, diagnosis, staging, treatment, outcomes, and follow-up were recorded. The National Comprehensive Cancer Network (NCCN) distress thermometer and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) were used to assess psychosocial morbidity of AYAs, children ≥ 12 years, and parents of children < 12 years. Pediatric Quality of Life Inventory (Peds QL) version 3.0 was used for children < 12 years. Data was analyzed using descriptive statistics. Results A total of 571 patients (512 AYAs, 59 children) were enrolled. Median age was 30 years with male predominance (58.1%). Most cases (98.6%) were absent from school or work. Carcinoma breast was the most common in females (29.3%) and non-Hodgkin lymphoma in males (12.6%). 91.06% had overall NCCN distress score ≥ 4. Also, 73.81 and 79.49% had "quite a bit" or "very much" responses on functional and symptom scales, respectively, in EORTC QLQ C-30 questionnaire. Peds QL version 3.0 revealed total score ranging from 276 to 523 for each patient. Conclusion AYAs and children with cancer are extremely vulnerable to psychological stress and morbidity. Use of well-established tools help in assessing their mental status and timely psychiatric referral can be initiated. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: adolescents and young adults and children; epidemiology; health-related quality of life; measurement tools; psychosocial morbidity
Year: 2021 PMID: 35833048 PMCID: PMC9273329 DOI: 10.1055/s-0041-1735482
Source DB: PubMed Journal: South Asian J Cancer ISSN: 2278-330X
Demography of different malignancies in the AYA study population
|
Types of malignancies (
| Frequency | Percentage | ||
|---|---|---|---|---|
| Astrocytoma | 20 | 3.5% | ||
| Carcinoma gallbladder/cholangiocarcinoma | 12 | 2.1% | ||
| Carcinoma breast | 71 | 12.4% | ||
| Carcinoma cervix | 7 | 1.2% | ||
| Carcinoma lung | 33 | 5.8% | ||
| Carcinoma nasopharynx | 11 | 1.9% | ||
| Carcinoma oral cavity | 19 | 3.3% | ||
| Carcinoma ovary | 12 | 2.1% | ||
| Carcinoma pancreas | 6 | 1.05% | ||
| Carcinoma parotid | 7 | 1.2% | ||
| Carcinoma thyroid | 39 | 6.8% | ||
| Carcinoma urinary bladder | 2 | 0.35% | ||
| Chondrosarcoma | 5 | 0.88% | ||
| Colorectal carcinoma | 38 | 6.65% | ||
| CUPS | 2 | 0.35% | ||
| Ewing's sarcoma | 16 | 2.80% | ||
| Gastric carcinoma | 12 | 2.1% | ||
| Germ cell tumor | 1 | 0.17% | ||
| Giant cell tumor | 5 | 0.88% | ||
| GIST | 2 | 0.35% | ||
| Glioblastoma multiforme | 12 | 2.1% | ||
| GTN | 4 | 0.7% | ||
| Hepatocellular carcinoma | 3 | 0.53% | ||
| Hodgkin's lymphoma | 37 | 6.48% | ||
| IMFT | 3 | 0.53% | ||
| LCH | 1 | 0.17% | ||
| Malignant melanoma | 2 | 0.35% | ||
| Medulloblastoma | 16 | 2.8% | ||
| Meningioma | 1 | 0.17% | ||
| MPNST | 2 | 0.35% | ||
| Multiple myeloma | 2 | 0.35% | ||
| NET | 1 | 0.17% | ||
| Neuroblastoma | 16 | 2.8% | ||
| Non-Hodgkin's lymphoma | 46 | 8.05% | ||
| NSGCT | 30 | 5.25% | ||
| Osteosarcoma | 14 | 2.45% | ||
| Renal cell carcinoma | 2 | 0.35% | ||
| Retinoblastoma | 1 | 0.17% | ||
| RMS | 6 | 1.05% | ||
| Seminoma | 16 | 2.8% | ||
| Soft tissue sarcoma | 29 | 5.08% | ||
| Thymic carcinoid | 1 | 0.17% | ||
| Wilms' tumor | 6 | 1.05% | ||
|
| ||||
|
|
|
|
| |
| CNS tumors | 2 (3.6%) | 1 (2.4%) | 10 (5%) | 20 (7.2%) |
| Carcinomas | 1 (1.8%) | 3 (7.1%) | 86 (43%) | 187 (67.5%) |
| Hodgkin lymphoma | 5 (8.9%) | 7 (16.7%) | 15 (7.5%) | 10 (3.6%) |
| Undifferentiated/embryonal tumors | 22 (39.3%) | 10 (23.8%) | 3 (1.5%) | 4 (1.4%) |
| Non-Hodgkin lymphoma | 3 (5.4%) | 2 (4.8%) | 26 (13%) | 15 (5.4%) |
| Bone tumors | 4 (7.1%) | 5 (11.9%) | 8 (4%) | 7 (2.5%) |
| Ewing's sarcoma | 6 (10.7%) | 4 (9.5%) | 3 (1.5%) | 3 (1.1%) |
| Soft tissue sarcomas | 2 (3.6%) | 4 (9.5%) | 18 (9%) | 13 (4.7%) |
| Seminoma | 1 (1.8%) | 1 (2.4%) | 8 (4%) | 7 (2.5%) |
| NSGCT | 0 (0%) | 5 (11.9%) | 20 (10%) | 5 (1.8%) |
| GTN | 0 (0%) | 0 (0%) | 2 (1%) | 2 (0.7%) |
| Melanoma | 0 (0%) | 0 (0%) | 0 (0%) | 2 (0.7%) |
| Neuroendocrine tumors | 0 (0%) | 0 (0%) | 1 (0.5%) | 2 (0.7%) |
| Wilms' tumor | 6 (10.7%) | 0 (0%) | 0 (0%) | 0 (0%) |
Abbreviations: AYA, adolescent and young adult; CNS, central nervous system; CUPS, carcinoma of unknown primary; GIST, gastrointestinal stromal tumor; GTN, gestational trophoblastic neoplasia; IMFT, inflammatory myofibroblastic tumor; LCH, Langerhans cell histiocytosis; MPNST, malignant peripheral nerve sheath tumor; NET, neuroendocrine tumor; NSGCT, non-seminomatous germ cell tumor; RMS, rhabdomyosarcoma.
Fig. 1Demographic distribution of cases. ( A ) Distribution according to different age subgroups. ( B ) Distribution of cases according to Birch classification. ( C ) Incidence of the 10 most common cancers among females. ( D ) Incidence of the 10 most common cancers among males.
Fig. 2The National Comprehensive Cancer Network (NCCN) Visual Analogue Scale. ( A ) Distribution of NCCN distress score. ( B ) Problem list with percentage of “yes” as response.
Fig. 3Distribution of cases with European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) response. ( A ) Overall functional scale. ( B ) Overall symptom scale. ( C ) Overall health score. ( D ) Overall quality of life score.
Fig. 4Distribution of cases using Pediatric Quality of Life Inventory (Peds QOL version 3) questionnaire response. ( A ) Peds QOL mean score of different age groups in each dimension assessed. ( B ) Distribution of cases according to the Peds QOL total score in the three age subgroups.